Overview
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
Status:
Completed
Completed
Trial end date:
2010-02-01
2010-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Portola PharmaceuticalsCollaborator:
Merck Sharp & Dohme Corp.Treatments:
Betrixaban
Criteria
Inclusion Criteria:- Able to understand and sign the written informed consent.
- Subjects should have either normal renal function or have stable renal disease
Exclusion Criteria:
- Subjects require dialysis
- Evidence of active bleeding or bleeding disorder
- Unstable or clinically significant other disorders such as respiratory, hepatic,
metabolic, psychiatric or gastrointestinal disorder